Comparison 3. Azole versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical cure	9	3440	Risk Ratio (M‐H, Random, 95% CI)	22.18 [12.63, 38.95]
1.1 Short‐term follow‐up (≤ 52 weeks)	7	2695	Risk Ratio (M‐H, Random, 95% CI)	23.89 [11.99, 47.64]
1.2 Long‐term follow‐up (> 52 weeks)	2	745	Risk Ratio (M‐H, Random, 95% CI)	19.11 [7.21, 50.65]
2 Mycological cure	9	3440	Risk Ratio (M‐H, Random, 95% CI)	5.86 [3.23, 10.62]
2.1 Short‐term follow‐up (≤ 52 weeks)	7	2695	Risk Ratio (M‐H, Random, 95% CI)	7.05 [2.91, 17.07]
2.2 Long‐term follow‐up (> 52 weeks)	2	745	Risk Ratio (M‐H, Random, 95% CI)	4.22 [2.34, 7.59]
3 Adverse events	9	3441	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.97, 1.12]
4 Recurrence rate	1	26	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.29, 1.07]